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This review describes pharmacologically active compounds from mushrooms. Compounds and complex
substances with antimicrobial, antiviral, antitumor, antiallergic, immunomodulating, anti-inflammatory,
antiatherogenic, hypoglycemic, hepatoprotective and central activities are covered, focusing on the
review of recent literature. The production of mushrooms or mushroom compounds is discussed briefly.
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Introduction
The medicinal use of mushrooms has a very long tradition in
the Asian countries, whereas their use in the Western hemi-
sphere has been slightly increasing only since the last decades.
The edition of the new scientific journal International Journal
of Medicinal Mushrooms (Begell house, Editor-in-Chief
S. P. Wasser), several books and reviews about medicinal
mushrooms (1–6) and biologically active compounds from
mushrooms (7) as well as international conferences about
this topic confirm this trend. The market value of medicinal
mushrooms and their derivative dietary supplements world-
wide was  US $1.2 billion in 1991 (8) and was estimated to
be US $6 billion in 1999 (9).
What is a ‘Mushroom’?
‘Mushroom’ is not a taxonomic category. The term ‘mush-
room’ should be used here according to the definition of Chang
and Miles as ‘a macrofungus with a distinctive fruiting body,
which can be either hypogeous or epigeous, large enough to
be seen with the naked eye and to be picked by hand’ (10).
From a taxonomic point of view, mainly basidiomycetes but
also some species of ascomycetes belong to mushrooms.
Mushrooms constitute at least 14000 and perhaps as many
as 22000 known species. The number of mushroom
species on the earth is estimated to be 140000, suggesting
that only 10% are known. Assuming that the proportion of
useful mushrooms among the undiscovered and unexamined
mushrooms will be only 5%, which implies 7000 yet
undiscovered species will be of possible benefit to
mankind (11). Even among the known species the proportion
of well investigated mushrooms is very low. This fact together
with the knowledge about the great potential of microscopic
fungi for production of bioactive metabolites [e.g. Penicillium,
Aspergillus, Tolypocladium inflatum W. Gams, Claviceps
purpurea (Fr.) Tul.], the experience in ethnomedicinal use of
mushrooms, the ecologic need for fungi to produce bioactive
secondary metabolites and the improved possibilities for gen-
etic, pharmacological and chemical analysis let us assume
that mushrooms have a great potential for successful biopro-
specting. This minireview should give an overview about the
present knowledge about the pharmacological potential of
mushrooms and related problems. Caterpillar fungi like
Cordyceps sinensis (Berk.) Sacc. or Paecilomyces tenuipes
(Peck) Samson are not closely allied to mushrooms. Because
they are used as valuable tonic foods and herbal medicines in
China and interesting investigations have recently been
published, they are discussed here, as well.
Antibacterial and Antifungal Mushrooms
Mushrooms need antibacterial and antifungal compounds
to survive in their natural environment. It is therefore not
surprising that antimicrobial compounds with more or less
strong activities could be isolated from many mushrooms
and that they could be of benefit for human (12). But only
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antibiotics till now.
Activities against Multiresistant Bacteria
Of special interest are compounds with activities against mul-
tiresistant bacterial strains. We could show that new sesquiter-
penoid hydroquinones produced by the European Ganoderma
species Ganoderma pfeifferi Bres. and named ganomycins
(1) inhibit the growth of methicillin-resistant Staphylococcus
aureus and other bacteria (13). Besides, we found that whole
extracts of this mushroom inhibit the growth of microorgan-
isms responsible for skin problems (Pityrosporum ovale,
Staphylococcus epidermidis, Propionibacterium acnes,
unpublished results).
Antimicrobial Activities of Known Compounds
Applanoxidic acid A (2a), isolated from Ganoderma annulare
(Fr.) Gilbn., shows weak antifungal activity against
Trichophyton mentagrophytes (14). Steroids like 5a-ergosta-
7,22-dien-3b-ol (3) or 5,8-epidioxy-5a,8a-ergosta-6,22-
dien-3b-ol (4), isolated from Ganoderma applanatum (Pers.)
Pat., proved to be weakly active against a number of gram-
positive and gram-negative microorganisms (15). Oxalic acid
is one agent responsible for the antimicrobial effect of
Lentinula edodes (Berk.) Pegler against S. aureus and other
bacteria (16). Ethanolic mycelial extracts from L. edodes
possess antiprotozoal activity against Paramecium caudatum
(17) (Figure 1). The antimicrobial activity of Podaxis
pistillaris (L.: Pers.) Morse, used in some parts of Yemen for
the treatment of ‘nappy rash’ of babies and in South Africa
against sun burn (18), is caused by epicorazins (5). These
substances belong to the group of epipolythiopiperazine-2,5-
diones, an important class of biologically active fungal
metabolites (18). Other antimicrobial compounds from the
Aphyllophorales were summarized by Zjawiony (7).
Antiviral Mushrooms
Incontrasttobacterialinfectiousdiseases,viraldiseasescannot
be treated by common antibiotics and specific drugs are
urgently needed. Antiviral effects are described not only for
whole extracts of mushrooms but also for isolated compounds.
They could be caused directly by inhibition of viral enzymes,
synthesis of viral nucleic acids or adsorption and uptake of
viruses into mammalian cells. These direct antiviral effects
are exhibited especially by smaller molecules. Indirect anti-
viral effects are the result of the immunostimulating activity
of polysaccharides or other complex molecules (19).
Small Molecular Compounds with Antiviral Activities
Several triterpenes from Ganoderma lucidum (M. A. Curtis:
Fr.) P. Karst. [i.e. ganoderiol F (6a), ganodermanontriol (7a),
ganoderic acid B (8a)] are active as antiviral agents against
human immunodeficiency virus type 1 (HIV-1) (Figure 2).
The minimum concentration of ganoderiol F (6a) and gano-
dermanontriol (7a) for complete inhibition of HIV-1 induced
cytopathic effect in MT-4 cells is 7.8 mgm l
 1. Ganoderic
acid B (8a) inhibits HIV-1 protease with an IC 50 value of
0.17 mM (20). Ganodermadiol (6b), lucidadiol (9a) and appla-
noxidic acid G (2c), isolated from G. pfeifferi, but also known
from other Ganoderma species, possess in vitro antiviral activ-
ity against influenza virus type A (IC 50 values in MDCK cells
>0.22; 0.22 and 0.19 mmol l
 1, respectively). Further, gano-
dermadiol (6b) is active against herpes simplex virus type 1,
causing lip exanthema and other symptoms [IC 50 in Vero
cells 0.068 mmol l
 1 (21)]. In vitro antiviral activity against
influenza viruses type A and B was demonstrated for mycelial
extracts of Kuehneromyces mutabilis (Schaeff.: Fr.) Singer &
A. H. Sm. (22), extracts and two isolated phenolic compounds
from Inonotus hispidus (Bull.: Fr.) P. Karst (23) and ergosterol
peroxide (4), present in several mushrooms (24). The antiviral
Figure 1. Lentinula edodes; Photo: Prof. Jan Lelley. Figure 2. Ganoderma lucidum; Photo: Prof. Jan Lelley.
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(vesicular stomatitis viruses in BHK cells) is caused by purine
derivatives (25).
High Molecular Compounds with Antiviral Activities
Water-soluble lignins isolated from Inonotus obliquus (Pers.:
Fr.) Pila ´t, commonly known as ‘Chaga’, inhibited HIV
protease with an IC 50 value of 2.5 mgm l
 1 (26). Anti-HIV
activities were reported for mycelial culture medium of
L. edodes (LEM) and water-soluble lignin in LEM (27,28).
Sulfated lentinan from L. edodes completely prevented
HIV-induced cytopathic effect (29). The protein-bound poly-
saccharides PSK and PSP (to the differences between both
substances see Table 1) from Trametes versicolor (L.: Fr.)
Pila ´t [syn. Coriolus versicolor (L.: Fr.) Quelet] were also
found to have an antiviral effect on HIV and cytomegalovirus
in vitro (30). Besides immunostimulation, other effects of the
polysaccharide–protein complexes contribute to the antiviral
activity, e.g. inhibition of binding of HIV-1 gp120 to immob-
ilized CD4 receptor and of reverse transcriptase activity of vir-
uses (31). Inhibition of HIV-1 reverse transcriptase was caused
by velutin, a ribosome inactivating protein from Flammulina
velutipes (M. A. Curtis: Fr.) P. Karst., as well (32). The
maitake D-fraction (MD-fraction) from Grifola frondosa
(Dicks: F) S.F. Gray was tested in a long-term trial with
35 HIV patients. A total of 85% of responders reported an
increased sense of well-being with regard to various symptoms
and secondary diseases caused by HIV (Figure 3). Twenty
patients showed an increase in CD4þ cell counts to 1.4–1.8
times and eight patients a decrease to 0.8–0.5 times (33).
Antitumor Mushrooms
Experience from Ethnomedicine
Tumor diseases are one of the main causes of death worldwide.
Experience from Asian and Eastern Europe countries shows
Table 1. Immunomodulating drugs from mushrooms (selected)
Mushroom scientific
name
Mushroom common
names
Immunomodulator Structure of immunomodulator(s) Selected
references
A. brasiliensis Royal sun Agaricus,
Himematsutake
FIo-a-b (1!6)-b-D-glucan, heteropolysaccharides,
polysaccharide–protein complex
(144,145)
FA-2-b-Md RNA–protein complex (MW 6200 daltons)
C. volvatus H-3-B (1!3)-b-D-glucan (146)
F. velutipes Winter mushroom, Enokitake Flammulin Protein (147)
G. lucidum Reishi, Ling Zhi GLP(AI), Ganopoly,
Ganoderans
b-D-glucans, heteropolysaccharides,
Glykoproteins
(148)
Protein LZ 8
G. frondosa Maitake, Hen-of-the-Woods MD-fraction (1!6)-b-D-glucan with
(1!3)-b-D side chains
(46,47)
Grifolan (1!3)-b-D-glucan with
(1!6)-b-D side chains
(149)
H. caput-medusae Syn.
H. erinaceus
Lion’s Mane, Monkey’s Head,
Yamabushitake
Glucoxylan; Heteroxyloglucan,
Glucoxylan–protein complex;
Galactoxyloglucan–protein complex
(40)
L. edodes Shiitake, Golden Oak
mushroom
Lentinan, KS-2 (1!3)-b-D-glucan with
(1!6)-b-D-glucosyl branches
(39,150)
LEM Complex mixture of polysaccharides
and lignin
Lentinus strigellus Polysaccharides (151)
P. linteus Polysaccharides (87,152)
S. commune Schizophyllan,
Sonifilan, SPG
(1!3)-b-D-glucan with
(1!6)-b-D-glucosyl branches
(5,49)
S. crispa Cauliflower mushroom SCG (1!3)-b-D-glucan with
(1!6)-b-D-glucosyl branches
(153)
T. versicolor Turkey Tail, Kawaratake, Yun Zhi Krestin (PSK), PSP PSK and PSP: heteroglucans with a(1!4)- and
b-( 1 !3) glycosidic linkages with a protein
component; the presence of fucose in PSK and
rhamnose and arabinose in PSP distinguishes
the compounds
(7,51,154)
T. fuciformis White Jelly fungus, Yin-erh Tremellastin Glucuronoxylomannans (125,155)
T. mesenterica
T. lobayense Polysaccharide–peptide complex (156)
Tricholoma mongolicum Mo-ku Lectin (157)
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treatment of cancer. Piptoporus betulinus (Bull.: Fr.) P. Karst.
was used traditionally in Bohemia for the treatment of rectal
cancer and stomach diseases (34). It is also known as fungus
of the ‘iceman’ from the Copper Age found in 1991, who car-
ried P. betulinus fruiting bodies attached to his clothing on his
journey in the Alps.
In Eastern Europe, the fruiting bodies of I. obliquus have
been used as a folk medicine for cancer and stomach diseases
since the 16th or 17th century (35). Antitumor effects of sev-
eral extracts and isolated compounds could be demonstrated
in tumor cell systems and in animal assays (36,37). Several
triterpenes and ergosterol peroxide contribute to the activity.
The melanin complex of I. obliquus has high antioxidant and
genoprotective effects on peroxidase-catalyzed oxidation of
aminodiphenyls (38).
So called ‘immunomodulators’ (biological response modi-
fier, immunopotentiators and immunostimulants) are the
most important medicinal mushroom drugs used especially in
Japan, China, Korea and other East Asian countries today.
They are summarized in the following sections.
Immunomodulators from Mushrooms and
Adjuvant Tumor Therapy
Polysaccharides from L. edodes, G. frondosa,
Schizophyllum commune and T. versicolor
Mode of Action
Some polysaccharides or polysaccharide–protein complexes
from mushrooms are able to stimulate the non-specific
immune system and to exert antitumor activity through the
stimulation of the host’s defence mechanism (39–42). The
drugs activate effector cells like macrophages, T lymphocytes
and NK cells to secrete cytokines like TNF-a, IFN-g, IL-1b,
etc., which are antiproliferative and induce apoptosis and
differentiation in tumor cells. Table 1 summarizes the most
important immunomodulators from mushrooms [for a more
extensive survey see (41,42)]. There is evidence that b-d-glu-
cans induce a biological response by binding to membrane
complement receptor type 3 (CR3, alphaMb2 integrin or
CD11b/CD18) on immune effector cells. The ligand–receptor
complex can be internalized. The intercellular events that
occur after glucan-receptor binding have not been fully
determined till now (43). In a recent experimental approach
it could be shown that schizophyllan produced by S. commune
Fr.: Fr. is able to bind the mRNA poly(A) tail (44). Molecular
weight, degree of branching, number of substituents, as well as
ultrastructure, including the presence of single and triple heli-
ces, significantly affect the biological activities of b-glucans
(45). Higher antitumor activity seems to be correlated with
higher molecular weight, lower level of branching and greater
water solubility of b-glucans (7). However, the high branched
MD-fraction from G. frondosa (MW 1000000–1200000 dal-
ton) exerts a high antitumor activity (46,47).
Clinical Trials
Lentinan from L. edodes, schizophyllan from S. commune,
MD-fraction from G. frondosa and compounds from
T. versicolor (PSK and PSP) are in clinical use (i.e.
0.5–1.0 mg lentinan per day, intravenous), especially in Japan
and China, for the adjuvant tumor therapy (immunotherapy) in
addition to the major cancer therapies like surgical operation,
radiotherapy and chemotherapy. Clinical studies have been
done especially in Asian countries [(reviewed in (1,3,4)].
Application of lentinan (parenteral) in addition to chemother-
apy led to prolongation of survival time, restoration of
immunological parameters and improvement of life quality
in patients with stomach cancer, colon cancer and other car-
cinomas in comparison to patients who had chemotherapy
alone (48). In a randomized multicentric study with 89 stom-
ach cancer patients, the median survival time in the immuno-
chemotherapy group (chemotherapy and lentinan 2 mg per
week, intravenous) was 189 days and in the control group
(only chemotherapy) 109 days (49). In another study of
patients with advanced colorectal cancer, the median survival
time was 200 days in the lentinan-treated group (2 mg per
week, 23 patients) and 94 days in the control group (50). In a
controlled randomized study, 130 patients were treated with
schizophyllan (intramuscular 40mg per week, totally
 1134 mg) after surgical removal of the whole tumor tissue
additionally to application of mitomycin and futraful. The
schizophyllan treatment started at day 14 after operation.
The median survival time after 5 years was 72.2% in the
schizophyllan group and 61.9% in the control group
(134 patients, chemotherapy only). Schizophyllan had no
effect on the survival time when the tumor tissue could not
be removed totally (51). In a randomized controlled study
with 462 curatively resected colorectal cancer patients, PSK
was given orally for >3 years following mitomycin C
(intravenous on the day of surgery and 1 day following) and
5-fluorouracil (orally for 5 months). The average study
Figure 3. Grifola frondosa; Photo: Prof. Jan Lelley.
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curve of the PSK group over the control group was statistically
significant (1,52). A controlled clinical trial of PSP was con-
ducted in 485 cancer patients (211 control patients, cancers of
the esophagus, stomach and lung). As a result of PSP admis-
sion [3 g per day, peroral (p.o.) 30 days], side effects from
the conventional therapy (esophagus cancer: Co
60-gamma
ray radiotherapy, DT 65–70 Gy per 6–7 months) significantly
lessened. PSP raised the 1 year survival rate of patients with
esophagus cancer by 11% (1,53).
The immunostimulating effect of lentinan was also investig-
ated in patients with AIDS. In a phase II study, 107 HIV
positive patients were treated with didanosin (400 mg per
day, p.o. 6 weeks). After that time, 88 patients got additionally
2 mg lentinan per week intravenous for 24–80 weeks, the
patients of the control group got only didanosin. The combined
treatment resulted in a significant increase of the number of
CD4þcellsafter38weeksincomparisontocontrolgroup(54).
In a non-random case series, a combination of MD-fraction
and whole powder of G. frondosa was investigated to deter-
mine its effectiveness for 22- to 57-year-old cancer patients
in stages II–IV. Cancer regression or significant symptom
improvement was observed in 58.3% of liver cancer patients,
68.8% of breast cancer patients and 62.5% of lung cancer
patients. The trial found a <10–20% improvement for
leukemia, stomach cancer and brain cancer patients (55).
MD-fraction appears to repress cancer progression and primar-
ily exerts its effect through stimulation of NK cells activity
(47). The MD-fraction has been approved by the Food and
Drug Administration (FDA) for an Investigational New Drug
application to conduct a phase II pilot study on patients with
advanced breast and prostate cancer (56).
Mode of Application
Effects could be shown after p.o. application, as well. The p.o.
application of lentinan to mice resulted in raised levels of
several cytokines. Lentinan, once ingested, may encounter
the gut-associated lymphoid tissue or may be absorbed into
the systemic circulation (57). Related effects of polysacchar-
ides from plants were explained by targeting immunocompet-
ent cells in the intestinal tract and recirculation of these cells
in the organism (58). An interesting option is the transfer of
lentinan-activated immune cells into immunodeficient mice.
Resulting tumor inhibition could be shown (57).
Polysaccharides from G. lucidum
Polysaccharides from G. lucidum (Ganopoly) are marketed as
over-the-counter-product in several Asian countries. Ganopoly
is composed of the polysaccharide fraction from the fruiting
bodies of wood-cultured G. lucidum (59). In a clinical study
with 100 patients with advanced solid cancer palliative effects
of Ganopoly (1800 mg, three times per day, p.o.) on
cancer-related symptoms, such as sweating and insomnia, have
been observed in many patients. Objective responses (com-
plete or partial disappearance of all tumor masses) could not
be found in this study (60). A randomized double-blind,
placebo-controlled, multicenter clinical trial with Ganopoly
(600 mg, three times per day p.o.) was done for 12 weeks in
68 patients with histologically confirmed advanced lung can-
cer. Patients were evaluated with respect to their extent of dis-
ease and quality of life (Karnofsky score), and hematological,
immunological and biochemical parameters. In 32 assessable
patients, treatment with Ganopoly resulted in a significant
increase in the KPS scores in 16 patients; 4 patients obtained
significant increase in the control group with 29 assessable
patients. Three episodes of mild toxicity (nausea, 2 and
insomnia, 1) were recorded in the verum group. Further stud-
ies are needed to explore the optimum dosing, efficacy and
safety alone or in combination with chemotherapy or radio-
therapy (59).
Polysaccharides from Sparassis crispa and Some
Further Mushrooms
Further mushrooms with immunomodulating polysaccharides
are used as delicious food or as health-promoting food
supplement (nutraceutical) or as drug in limited geographic
regions. Scientific or clinical studies are not sufficient for use
as ‘official’ drug worldwide till now. However, some
examples should be reported.
In a small clinical trial, powder of S. crispa (Wulfen): Fr.
(300 mg per day) was given orally to several cancer patients
after one course of lymphocyte transfer immunotherapy.
Performance status of 14 cases were monitored after several
months, and 9 cases were improved (61,62). In China, several
preparations from Hericium caput-medusae (Bull.: Fr.) Pers.
[syn. Hericium erinaceus (Bull.: Fr.) Pers.] are on the market
for treating chronic stomach diseases and other purposes
(63). Agaricus brasiliensis Wasser et al. is a new cultivated
medicinal and gourmet mushroom with benzaldehyde and
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volatile fraction (64). Because the North American endemic
species Agaricus blazei Murrill and the widely cultivated
medicinal A. blazei ss. Heinem. proved to be different species,
A. blazei ss. Heinem. was described as a new species,
A. brasiliensis (65). The biggest group of active substances is
composed of polysaccharides, obtained from fruit bodies,
mycelium and culture filtrate (66,67). Acetone extract of fruit
bodies contained six antitumor-active steroids (66). Antimuta-
genic effects were also found (68).
Cytostatic Activities
High Molecular Compounds with Cytostatic Activities
Cytostatic activities against tumor cells were shown in vitro
for several mushrooms or mushroom components, e.g.
ubiquitin-like proteases [peptide with a MW of 8 kDa, (69)]
from the fruiting bodies of Handkea utriformis (Bull.: Pers.)
Kreisel [syn. Calvatia caelata (Bull.) Morgan], ribosome
inactivating proteins, e.g. from Hypsizygus marmoreus
(Peck) H. E. Bigelow [hypsin, (70)], F. velutipes [flammulin
and velutin (32)] and other mushrooms and lectins from
Agaricus bisporus (J. E. Lange) Imbach (71) or Pleurotus
ostreatus (Jacq.: Fr.) P. Kumm. [also in vivo effects (72)].
The contribution of these high molecular weight molecules to
an in vivo effect of mushrooms after p.o. application remains
unclear. Cancer protective effects of P. ostreatus fruit bodies
were demonstrated in rats (73). Besides, P. ostreatus dimin-
ishes the toxicity of cyclophosphamide in mice (74). The
ethylacetate extract (50 mg kg
 1 p.o. per day) of the sporo-
carps of Phellinus rimosus (Berk.) Pila ´t. possess significant
antitumor activity comparable to the activity of cisplatin
(4 mg kg
 1 per day, intraperitoneal) in ascites and solid tumor
models in mice (75).
Small Molecular Compounds with Cytostatic Activities
Many small molecular weight compounds exhibit cytotoxic
activities against tumor cells. To them belong the illudins,
tricyclic sesquiterpenes from Omphalotus olearius (DC.: Fr.)
Singer and Lampteromyces japonicus (Kawam.), Singer and
their derivatives (76), the terpenoid leaianafulvene (10) from
Mycena leaiana (Berk.) Sacc. (77), triterpenes [ganoderic
acids Z (8b), Y, X, W, V, T; lucialdehydes A, B, C (9b) and
australic acid (11)] from G. lucidum (78–80) or Ganoderma
australe (Fr.) Pat. (81), acetoxyscirpenediol (12), ergosterol
peroxide (4) from P. tenuipes (82) and sterols from the mycelia
of C. sinensis (Berk.) Sacc. (83). Acetoxyscirpenediol (12)
exerts its activity by inducing apoptosis in leukemia cell lines
in vitro (84). Apoptosis in HL-60 cells could be induced by
triterpenes from Ganoderma concinnum Ryvarden [i.e.
5a-lanosta-7,9(11),24-triene-15a-26-dihydroxy-3-one (6c)],
as well (85). The triterpenes applanoxidic acid A-H (2),
isolated first from G. applanatum, were effective against
mouse skin tumor promoters, applanoxidic acid B (2b) being
the most potent of the acids. The activities were shown in the
short-term in vitro assay of Epstein–Barr virus early antigen
activation in Raji cells induced by 12-O-tetradecanoyl-
phorbol-13-acetate (86,87). A derivative of illudin S (13) has
progressed to phase II human clinical trials (88). The specifi-
city of the cytotoxic action against tumor cells remains to
determine.
Cytostatic Compounds with Specific Targets
Recently, more attention is given to the identification of
molecular pathogenesis mechanisms of cancer. In this connec-
tion more specialized targets for potential antitumor drugs
were identified. It could be shown that some compounds
from mushrooms act on such targets. Some examples are
provided below.
Ganoderic acids A (8c) and C (8d) from G. lucidum are
inhibitors of farnesyl protein transferase. Because this enzyme
participates in Ras-dependent cell transformation, inhibitors
represent a potential therapeutic strategy for the treatment of
cancer (89). Phellinus linteus (Berk. & M. A. Curtis) Teng
was found to contain antiangiogenic activity in the chick
embryo chorioallantoic membrane assay (90) and to inactivate
cancer-related kinases (91). Antiangiogenic activity was also
reportedfor polysaccharides from A. brasiliensis (92).The ses-
quiterpenoid cryptoporic acids A-G (14) from Cryptoporus
volvatus (Peck) Murrill inhibit the tumor promotion activity
of okadaic acid in two-stage carcinogenesis experiments.
The effect is possibly related to their strong radical scaveng-
ing activity (93). Antimutagenic effects were found for
methanolic extracts of P. ostreatus (94), methanolic extracts
of Lactarius vellereus (Fr.) Fr. (95) and for water extracts
of A. bisporus and G. lucidum. The genoprotective effect of
A. bisporus has been related to the enzyme tyrosinase (96).
A dried oyster mushroom (P. ostreatus) diet (5%) reduced
pathological changes in dimethylhydrazine-inducedcolon can-
cer in rats but did not influence significantly the incidence of
tumors. This effect is explained by the antioxidant properties
of this mushroom and by its fiber content (97).
Immunosuppressive and Antiallergic
Mushrooms
Although extracts of many mushrooms can stimulate the
immune system, some suppress immune responses. This could
be of interest, e.g. for the treatment of allergic diseases that
are increasing worldwide.
Inhibition of Allergic Reactions
Ethanolic extracts of the edible Japanese basidiomycetes
H. marmoreus, F. velutipes, Pholiota nameko (T. Ito) S. Ito
and Pleurotus eryngii (DC.: Fr.) Que ´l. show significant
antiallergic effects in mice (oxazolone-induced type IV
allergy) also after p.o. application (98). Some compounds
from G. lucidum [ganoderic acids C (8d) and D (8e);
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cells (99,100). Eating of Tricholoma populinum J. E. Lange
led to the regression of severe allergic symptoms in a patient
with thromboangitis obliterans and in another patient with
urticaria. The effects could be confirmed in animal models,
as one responsible compound ergosterol peroxide (4) was iden-
tified (101,102). Hispolon (15) and hispidin (16), isolated from
fruit bodies of I. hispidus, inhibit the chemiluminescence
response of human mononuclear blood cells and the mitogen-
induced proliferation of spleen lymphocytes of mice (103).
Influence on Lipopolysaccharide Binding
Septic shock is a complex syndrome mediated by binding
of lipopolysaccharide (LPS) from gram-negative bacteria to
CD14 receptor on immune cells and the following release of a
cascade of inflammatory mediators and reactive oxygen spe-
cies. Because of the large number of patients with septic shock
a great deal of effort is necessary to develop new therapeutic
possibilities. Extracts of the fruiting bodies of Polyporus
badius (Gray) Schwein., L. vellereus (Fr.) Fr., Heterobasidion
annosum (Fr.) Bres., T. versicolor and P. betulinus inhibit
in vitro binding of LPS to the receptor (104) and could there-
fore contain lead structures for drugs against LPS-mediated
septic shock.
Anticomplement Activities
Activation of the complement system, inducing the release of
mediators from mast cells, can cause a variety of diseases
and can be fatal if occurring after an organ transplantation.
Several triterpenes from G. lucidum [ganoderiol F (6a), gano-
dermanontriol (7a) and ganodermanondiol (7b)] show strong
anticomplement activity against the classical pathway of the
complement system with IC 50 values of 5–40 mM (105).
Antiatherogenic Mushrooms
Influence on Blood Lipids
Reactive oxygen species and increased levels of blood lipids
are key elements in the pathogenesis of atherosclerosis, one
of the main causes of death in industrial countries. The control
of blood lipids, especially cholesterol, is important for
reducing the risk of the development or progression of athero-
sclerosis. A pronounced hypocholesteremic effect of oyster
mushroom (P. ostreatus), combined with inhibition of lipid
peroxidation, was shown in rats and rabbits. Oyster mushroom
diet (10% dried fruiting bodies) significantly reduced the
incidence and size of atherosclerotic plaques in rabbits (106).
Lovastatin (18), the lead compound for the statines (HMG-
CoA reductase inhibitors), could be detected in this species
(107) and is jointly responsible for the observed effects.
Hypocholesteremic effects of Auricularia auricularia-judae
(Bull.: Fr.) Wettst. and Tremella fuciformis Berk. are
explained by similar mechanisms (1,108,109).
Antioxidative and Other Biological Activities
Some triterpenes from G. lucidum [ganoderic acid C (8d) and
derivatives] are able to inhibit the biosynthesis of cholesterol,
as well (110). Other triterpenes of this fungus contribute to
atherosclerosis protection by inhibition of angiotensin con-
verting enzyme [ganoderic acid F (8f) (111)] or of platelet
aggregation [ganoderic acid S (17b) (112)]. The antioxidative
and free radical scavenging effects of polysaccharides and
triterpenoids from G. lucidum were shown in different oxidat-
ive injury models including tert-butylhydroperoxide damaged
mice peritoneal macrophages, alloxan-induced diabetes and
experimental liver injury models. The inhibition of low density
lypoproteins (LDL) oxidation by endothelial cells and of
monocyte adhesion to endothelial cells has been demonstrated
(113). The antilipidemic effect of L. edodes is caused by erit-
adenin (19), a nucleotide derivative (114).
p-Terphenyl compounds from Thelephora ganbajun
M. Zang, Thelephora aurantiotincta Corner, Boletopsis grisea
(Peck) Bondartsev & Singer (115) as well as from Paxillus
curtissii Berk. (116) showed strong antioxidative properties.
Betulinan A (20) from Lenzites betulinus (L.: Fr.) Pila ´t is about
four times more active as a radical scavenger than vitamin E in
inhibition of lipid peroxidation (117). Lipid peroxidation is
also inhibited by the sterins A and B from Stereum hirsutum
(Willd.: Fr.) Pers. (118).
Ergosta-4-6-8(14),22-tetraen-3-one (21),isolablefrommany
mushrooms, has been shown to possess antialdosteronic
diuretic properties (119).
Potentiators of ADP-induced platelet aggregation have been
found in Polyporus umbellatus (Pers.): Fr. (Cho-Rei)
[5a,8a-epidioxy-ergosta-6,22-dien-3-ol (4)] and others (120).
Hypoglycemic Mushrooms
Diabetes mellitus is a metabolic disorder affecting
 250 million people worldwide. More effective and safer
treatment modalities for type 2 diabetes patients need to be
investigated, focusing on overcoming peripheral insulin resist-
ance. A polysaccharide fraction of G. frondosa (SX fraction,
p.o.) showed hypoglycemic action in five patients with type
2 diabetes (56).
Ganoderan A and B, glucans from G. lucidum fruiting bodies
(121), coriolan, a b-glucan–protein complex obtained from
submerged grown T. versicolor biomass (122) and an acidic
glucuronoxylomannan from the fruiting bodies of Tremella
aurantia Schwein. (123) exhibited hypoglycemic effects in
several test systems and ameliorated the symptoms of diabetes.
Seventy-one patients with confirmed type 2 diabetes were
treated with polysaccharide fractions from G. lucidum
(Ganopoly, 1800 mg three times daily for 12 weeks). At
week 12, mean post-prandial glucose values had decreased to
11.8 mmol l
 1 in the Ganopoly group [significant difference
to placebo group, (124)].
Tremellastin, containing 40–45% acidic polysaccharide
glucuronoxylomannan and obtained by alcohol precipitation
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well as triglyceride levels in rats after 15 treatment days
(p.o. 100 mg kh
 1; 500 mg kg
 1). Hypoglycemic effects in
glucose-loading and streptozotocin-induced hyperglycemic
rats could not be found (125).
Preparations from the traditional Chinese drug Cordyceps
(consisting of fungi parasitic in insects) and from fermented
mycelia meliorate diabetes in a diabetic animal model
using streptozotocin-induced rats after p.o. application (126).
Crude polysaccharides from cultured mycelium of
Cordyceps have shown significant activity after intraperitoneal
injection (127). Besides, Cordyceps is highly appreciated
by Chinese medical practitioners as a treatment for many
ailments (128).
Dehydrotrametenolic acid (22), found in several polypores
including Wolfiporia cocos (Schwein.) Ryvarden & Gilbn.,
Laricifomes officinalis (Vill.: Fr.) Kotl. & Pouzar (syn.
Fomitopsis officinalis (Vill.: Fr.) Bondartsev & Singer and
Laetiporus sulphureus (Bull.: Fr.) Murrill, acts as an insulin
sensitizer in glucose tolerance tests and reduces hyperglycemia
in mice with noninsulin-dependent diabetes (129).
Anti-inflammatory Mushrooms
Ethanolic extracts and a proteoglycan from P. linteus show
anti-inflammatory effect in the collagen-induced arthritis and
in the croton oil-induced ear edema test in mice and antino-
ciceptive effect in the writhing test (90,130). Other compounds
effective in the writhing test are the ganoderic acids A (8c),
B( 8a), G (8g) and H (8h), isolated from G. lucidum. These
substances showed a stronger effect in this animal model
than acetylsalicylic acid (131).
Methanolic extract of Pleurotus pulmonarius (Fr.)
Que ´l. fruiting bodies (500 and 1000 mg kg
 1) reduced
carrageenan-induced and formalin-induced paw edema in
mice. The activity was comparable to the reference
diclofenac (10 mg kg
 1). The effect seemed to be related to
the significant antioxidant activity of the extract. The IC 50
value for hydroxyl-radical scavenging was 476 mgm l
 1
and for lipid peroxidation inhibition 960 mgm l
 1. Besides,
the extract showed significant solid tumor-reducing activity
in mice (132).
The edible mushroom G. frondosa contains ergosterol,
ergosta-4-6-8(14),22-tetraen-3-one (21) and 1-oleoyl-2-
linoleoyl-3-palmitoylglycerol, which inhibit cyclooxygenases
1 and 2 activity (133).
Hepatoprotective Mushrooms
Ganoderic acids R (17a) and S (17b) and ganosporeric acid
A( 8i) from G. lucidum show in vitro antihepatotoxic activity
in the galactosamine-induced cytotoxic test with primary cul-
tured rat hepatocytes (134,135). In vivo two fractions of a total
triterpenoids extract of G. lucidum (75% ethanol) can protect
mice against hepatic necrosis induced by chloroform and
d-galactosamine. The hepatoprotective effects were perhaps
related to the ability to promote the activity of scavenging
enzymes for hepatic free radicals in mice, and thus to raise
the ability of antioxidation in mice (136).
Ganopoly, the polysaccharide-containing preparation of
G. lucidum, was proven in a double-blind, randomized and
multicentered study in patients with chronic hepatitis B
(HBV DNA positive; application of Ganopoly for 12 weeks,
then 13 weeks followed up, 600 mg three times per day equal
to 27 g fruiting body, p.o.). Within the 6 months study period,
33% (17/52) of treated patients had normal aminotransferase
values and 13% (7/52) had cleared hepatitis B surface antigen
from serum, whereas none of the controls had normal enzyme
values or had lost HBsAg. The drug was well tolerated (137).
Mushrooms with Central Activities
Apart from well investigated psychoactive mushrooms like
Amanita muscaria (L.: Fr.) Pers. or Psilocybe species some
further mushroom extracts and compounds have been found
with special central effects that could be of pharmacological
interest.
Phenol-analogous compounds [hericenons C (23), D, E, F,
G, H] from H. erinaceus induce the synthesis of nerve growth
factor and might have an ameliorative effect in Alzheimer’s
dementia (63). Erinacin E (24) from Hericium coralloides
(Scop.: Fr.) Gray [syn. Hericium ramosum (Me ´rat) Letell.]
fermentation broth is a highly selective agonist at the kappa
opiod receptor (IC 50 of 0.8 mM, binding at the m opiod recep-
tor with an IC 50 of >200 mM). Such compounds may exhibit
antinociceptive activity without side effects observed with
m receptor agonists like morphine (138).
Screening investigations of selected basidiomycetes indicate
inhibitory effects of P. betulinus, G. applanatum, H. annosum,
Fomitopsis pinicola (Sowerby: Fr.) P. Karst and Daedaleopsis
confragosa (Bolton: Fr.) J. Schro ¨t. on neutral endopeptidase
(enkephalinase, EC 3.4.24.11) (IC 50 values between 40 and
55 mgm l
 1). Selective inhibitors of this metalloendopeptidase
could be useful in the treatment of pain with a spectrum of
activity similar to that of opioids (139).
Scutigeral (25), isolated from fruiting bodies of Scutiger
ovinus (Schaeff.: Fr.) Murrill [syn. Albatrellus ovinus
(Schaeff.: Fr.) Kotl. & Pouzar], has affinity to the brain
dopamine D1 receptors and may act as an orally active pain
killer targeting vanilloid receptors [VR1, (140)]. Albaconol
(26) from the fruiting bodies of Scutiger confluens (Alb. &
Schwein.: Fr.) Bondartsev & Singer [syn. Albatrellus conflu-
ens (Alb. & Schwein.: Fr.) Kotl. & Pouzar is an antagonist at
the VR1 receptor with an IC 50 value of 5 mM (141).
Production of Pharmacologically Interesting
Mushrooms or Compounds
In principle, whole mushrooms (mainly fruiting bodies),
extracts (from fruiting bodies or mycelium) and isolated
compounds are suitable for use. The material could be
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rooms in farms and harvesting of the fruiting bodies or by
cultivation of mycelium in fermenters with liquid or solid
substrates. Extracts could be prepared by extraction of
mushrooms (dried or fresh) with suitable solvents. Pure com-
pounds could be obtained by isolation from the natural or
cultivated material or by chemical synthesis. Very often, the
natural compound serves as lead compound for the preparation
of a high variety of derivatives. Because most mushrooms can
be cultivated in an economic matter, the production of mush-
room compounds, especially proteins, by genetically modified
organisms seems not to be necessary.
At present, between 80 and 85% of all medicinal mushroom
products are derived from the fruiting bodies, which have been
either commercially farmed or collected from the wild, for
example, lentinan and various products from G. lucidum.
Only  15% of all products are based on extracts from mycelia.
Examples are PSK and PSP from T. versicolor and tremellastin
from Tremella mesenterica. (Retzius): Fr. A small percentage
of mushroom products are obtained from culture filtrates,
e.g. schizophyllan from S. commune and protein-bound
polysaccharidecomplexfromMacrocybelobayensis(R.Heim)
Pegler & Lodge [syn. Tricholoma lobayense R. Heim (142)].
After production, suitable galenic formulations like cap-
sules, tablets or teas have to be developed, dependent on the
material. Mixtures of several mushrooms or of mushroom
and substrate become more and more common (9).
Summary and Outlook
The review demonstrates that mushrooms, similar to plants,
have a great potential for the production of useful bioactive
metabolites and that they are a prolific resource for drugs.
The responsible bioactive compounds belong to several
chemical groups, very often they are polysaccharides or triter-
penes. One species can possess a high variety of bioactive
compounds, and therefore of pharmacological effects. The
best example is G. lucidum, which not only contains >120
different triterpenes but also polysaccharides, proteins and
other bioactive compounds (43,143).
The spectrum of detected pharmacological activities of
mushrooms is very broad. Dependent on increasing knowledge
about chemistry, biotechnology and molecular biology of
mushrooms as well as an improvement of screening methods
(high throughput screening, genomics and proteomics), a rapid
increase in the application of mushrooms for medicinal
purposes can be expected.
Prerequisition for a use as drug, nutraceutical or other
purpose is the continuous production of mushrooms (fruiting
bodies or mycelium) in high amounts and in a standardized
quality. In the opinion of Chang (142), mycelial products are
the ‘wave of the future’ because they ensure standardized
quality and year around production. A further necessity is the
establishment of suitable quality parameters and of analytical
methods to control these parameters. Nevertheless, the legal
regulations for authorization as drug or as dietary supplements
or as food should get more attention (9). Control of possible
side effects (i.e. allergies) during broad use is necessary.
Finally, also the nutritional value of mushrooms should be
taken into account.
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